Navigation path



Vaccine Strategies for Combined Targeting of Innate and Adaptive Immune Pathways
Framework programme:
Project number:
EC contribution:
€ 1,000,000
24 months
Starting date:
May 2005

Keywords: HIV; vaccine; adjuvant; viral vector; innate immune responses


Most candidate vaccines specific for HIV-1 are designed to stimulate cell-mediated immune responses. These include different viral and non-viral vectors and a combination of prime/boost protocols. Preliminary data already suggest that the immune responses elicited by these vaccines are limited and likely to be insufficient for protection. In this project, the aim is to enhance both cell-mediated and neutralising antibody responses by the use of two novel adjuvants that target innate and adaptive immunity, respectively: bacterial Flagellin via Toll-like receptor 5 signaling and polymeric (Mega) CD40 ligand via stimulation of CD40 on dendritic cells and lymphocytes. In addition, a new approach for adjuvant signaling will be developed with a novel alphavirus vaccine virus replicon vector of Semliki Forest virus, a virus which recently has been shown to strongly target the innate immune pathways including Toll-like receptors. The novel adjuvant strategies will be combined to existing vaccines and analysed as to whether such treatment can shape the immune responses into effective responses. Studies will be performed in human and murine settings (based amongst others on analysis of T and B cell memory responses) to get key comparative information for the development of new formulation of HIV-specific vaccines. The effect of the adjuvants and vectors on innate immune signals will also be thoroughly characterised. Finally, vaccines and vaccine-adjuvant combinations also using alphavirus and poxvirus vectors will be evaluated in animal challenge models to obtain immune correlates of protection. This project will provide the basis for a more effective HIV vaccine.

[+] Read More